BrightPath Biotherapeutics Co., Ltd. (4594.T)
JPY 39.0
(0.0%)
JPY 39.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.15 Billion JPY | 21.27% |
| 2022 | -1.46 Billion JPY | 0.61% |
| 2021 | -1.47 Billion JPY | 14.82% |
| 2020 | -1.73 Billion JPY | 5.17% |
| 2019 | -1.82 Billion JPY | -9.71% |
| 2018 | -1.66 Billion JPY | -6.65% |
| 2017 | -1.56 Billion JPY | -40.25% |
| 2016 | -1.11 Billion JPY | -12.62% |
| 2015 | -988.75 Million JPY | -100.89% |
| 2014 | -492.18 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -326.97 Million JPY | -57.27% |
| 2023 Q2 | -257.13 Million JPY | 12.37% |
| 2023 Q1 | -293.43 Million JPY | -17.99% |
| 2023 Q3 | -396.6 Million JPY | -54.24% |
| 2023 FY | -1.15 Billion JPY | 21.27% |
| 2023 Q4 | -207.9 Million JPY | 47.58% |
| 2022 Q4 | -248.68 Million JPY | 39.83% |
| 2022 Q3 | -413.3 Million JPY | -59.18% |
| 2022 FY | -1.46 Billion JPY | 0.61% |
| 2022 Q2 | -259.64 Million JPY | 52.4% |
| 2022 Q1 | -545.42 Million JPY | -35.57% |
| 2021 Q3 | -352.24 Million JPY | -10.46% |
| 2021 Q1 | -402.57 Million JPY | 9.06% |
| 2021 Q4 | -402.31 Million JPY | -14.21% |
| 2021 Q2 | -318.89 Million JPY | 20.79% |
| 2021 FY | -1.47 Billion JPY | 14.82% |
| 2020 Q4 | -442.68 Million JPY | 14.51% |
| 2020 FY | -1.73 Billion JPY | 5.17% |
| 2020 Q1 | -408.89 Million JPY | 18.61% |
| 2020 Q2 | -363.39 Million JPY | 11.13% |
| 2020 Q3 | -517.83 Million JPY | -42.5% |
| 2019 Q2 | -420.62 Million JPY | 0.64% |
| 2019 Q4 | -502.36 Million JPY | -4.44% |
| 2019 Q1 | -423.33 Million JPY | -9.82% |
| 2019 Q3 | -481.02 Million JPY | -14.36% |
| 2019 FY | -1.82 Billion JPY | -9.71% |
| 2018 FY | -1.66 Billion JPY | -6.65% |
| 2018 Q4 | -385.48 Million JPY | 15.08% |
| 2018 Q3 | -453.96 Million JPY | -5.96% |
| 2018 Q2 | -428.43 Million JPY | -7.74% |
| 2018 Q1 | -397.65 Million JPY | -1.39% |
| 2017 Q1 | -262.07 Million JPY | 36.75% |
| 2017 Q2 | -423.84 Million JPY | -61.73% |
| 2017 Q3 | -483.6 Million JPY | -14.1% |
| 2017 Q4 | -392.2 Million JPY | 18.9% |
| 2017 FY | -1.56 Billion JPY | -40.25% |
| 2016 FY | -1.11 Billion JPY | -12.62% |
| 2016 Q3 | -230.36 Million JPY | 17.98% |
| 2016 Q2 | -280.88 Million JPY | -49.44% |
| 2016 Q1 | -187.95 Million JPY | 6.87% |
| 2016 Q4 | -414.34 Million JPY | -79.86% |
| 2015 FY | -988.75 Million JPY | -100.89% |
| 2015 Q4 | -201.81 Million JPY | -11.98% |
| 2015 Q3 | -180.22 Million JPY | 43.02% |
| 2015 Q1 | -290.41 Million JPY | 0.0% |
| 2015 Q2 | -316.28 Million JPY | -8.91% |
| 2014 FY | -492.18 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 293.538% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | -132.472% |
| GNI Group Ltd. | 13.1 Billion JPY | 108.811% |
| Linical Co., Ltd. | 725.72 Million JPY | 259.162% |
| Trans Genic Inc. | 89.43 Million JPY | 1391.515% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 18.996% |
| Soiken Holdings Inc. | -610 Million JPY | -89.355% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | -49.478% |
| AnGes, Inc. | -11.96 Billion JPY | 90.348% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | -3.059% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 87.874% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | 1207.469% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | -33.626% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | -3.411% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 8.472% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | -44.646% |
| RaQualia Pharma Inc. | -337.36 Million JPY | -242.383% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 4.156% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 13.516% |
| PeptiDream Inc. | 6.77 Billion JPY | 117.054% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 40.151% |
| Ribomic Inc. | -1.11 Billion JPY | -3.484% |
| SanBio Company Limited | -4.53 Billion JPY | 74.552% |
| Healios K.K. | -3.37 Billion JPY | 65.816% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 17.11% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 17.671% |
| StemRIM | -2.07 Billion JPY | 44.36% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 194.562% |
| FunPep Company Limited | -994 Million JPY | -16.205% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -29.965% |
| Stella Pharma Corporation | -760.3 Million JPY | -51.924% |
| TMS Co., Ltd. | -943.25 Million JPY | -22.457% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -48.967% |
| Cuorips Inc. | -588.48 Million JPY | -96.279% |
| K Pharma,Inc. | 366.05 Million JPY | 415.546% |
| Takara Bio Inc. | 3 Billion JPY | 138.464% |
| ReproCELL Incorporated | -409.29 Million JPY | -182.213% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | 10540.92% |
| StemCell Institute Inc. | 413.75 Million JPY | 379.167% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | 899.324% |
| CellSeed Inc. | -697.77 Million JPY | -65.537% |